Norges Bank Xilio Therapeutics, Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.55 - $3.46 $310,811 - $421,729	-121,887 Closed	0 $0
Q2 2022 Aug 14, 2023	BUY	$2.08 - $7.2 $253,524 - $877,586	121,887 New	121,887 $355,000
Q1 2022 May 12, 2023	BUY	$6.63 - $16.05 $2.65 Million - $6.42 Million	400,000 New	400,000 $2.83 Million
Q1 2022 May 09, 2022	SELL	$6.63 - $16.05 $2.65 Million - $6.42 Million	-400,000 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$9.69 - $25.11 $3.88 Million - $10 Million	400,000 New	400,000 $6.4 Million

12.6M

Ticker XLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,471,600
Market Cap $20.9M
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.